How Glucagon-Like Peptide-1 Receptor Agonists May Reduce Artery Plaque: Direct or Indirect Actions?

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce major adverse cardiovascular events in patients with and without Type 2 diabetes.

• GLP-1 RAs are associated with improvements in lipid metabolism, insulin sensitivity, and blood pressure.
• Direct vascular actions of GLP-1 RAs may include anti-inflammatory effects and suppression of oxidative stress.
• These agents could improve endothelial function and modulate the behavior of immune cells in the vasculature.
• GLP-1 RAs may inhibit the proliferation and migration of vascular smooth muscle cells.
• The mechanisms underlying these effects are mostly derived from preclinical or animal studies, indicating a need for further research in humans.

Simplified